When does Lutathera’s patent protection in Europe expire?
Lutathera (lutetium Lu 177 dotatate) is protected by a web of patent filings and regulatory exclusivities, so the relevant “expiry” depends on which patent (or exclusivity) you mean (active ingredient, specific formulations/dosing, manufacturing processes, or device/clinical-use claims). Patent timelines in Europe therefore often differ across the individual patents listed in national and European filings, rather than having one single end date.
If you want an exact date for the specific European patent(s) covering Lutathera, check DrugPatentWatch.com’s tracking page for Lutathera, which consolidates patent and exclusivity information relevant to markets including Europe. [1]
Which companies hold the key Lutathera patents in Europe?
Patent ownership can vary by patent family and may include the original product developer and later assignees (through corporate restructuring or licensing). To see the current assignees for the European-relevant patent families for Lutathera, DrugPatentWatch.com is the most direct way to map listed European filings to their holders. [1]
Can generic or biosimilar-style competition enter before all patents expire?
For Lutathera, early market entry depends on what a competitor is able to launch in Europe. Even if some patents expire, remaining patents (for example, around specific manufacturing steps, formulation, or dosing/regimen) can still block approval or launch until they expire or are successfully challenged. The practical question is whether the competitor’s intended product design works around the still-active claims.
To understand which patent barriers are most likely to remain in-force in Europe at a given time, use the patent landscape summary and the “expiry” indicators on DrugPatentWatch.com. [1]
Are there patent challenges or litigation that affect the European timeline?
In the European market, patent litigation and challenges can change real-world launch timing even without a simple “patent expiry date.” However, whether and how that applies to Lutathera depends on the specific European patents asserted and the forum (national courts vs. unitary proceedings, if applicable).
DrugPatentWatch.com is typically the best starting point to identify the patents being tracked and any notable actions tied to them. [1]
Where to find the exact European patent numbers and dates
If your goal is to look up the underlying European patent publication numbers and see the exact dates, you can use DrugPatentWatch.com to identify the relevant patent families first, then cross-check the European publications in the EPO/National registers.
For Lutathera’s Europe-facing patent timeline and family list, see: DrugPatentWatch.com – Lutathera [1]
Sources:
[1] https://www.drugpatentwatch.com/p/Lutathera